John T. Booth

Coleman Swenson Booth (CSB) invests in the healthcare services, medical devices, medical products, biotechnology, information systems/technology and Internet-based healthcare applications sectors. They invest through four funds: Franklin Capital Associates LP (FCA), Franklin Capital Associates II LP (FCA II), Franklin Capital Associates III LP (FCA III) and Coleman Swenson Hoffman Booth IV LP (CSHB IV). The portfolios of FCA and FCA II were balanced between the product and service segments of the healthcare industry. FCA III invested primarily in privately-held services, information systems and telecommunication companies exclusively in the healthcare industry. CSHB IV serves as a later-stage source of funding. Coleman Swenson usually serves as lead investor in the financing and is represented on the Board of Directors of a portfolio company. Investments range from $1 million to $7 million. The majority of their investments are in seed and start-up companies. The companies in which CSB invests must provide healthcare or life sciences related products, services or information technologies. They seek companies with products or services capable of providing a major, favorable impact on the cost or efficacy of healthcare delivery. Companies should fulfill a major need, serve a demonstrably large market, have strong and experienced management and have significant barriers to competitive entry or a proprietary position in the market place. The appropriate return on the investment should be consistent and realizable with the perceived risk. CSB is flexible relative to the investment instrument employed. Investments are actively pursued in both small, high-risk enterprises and more mature, but growing, companies.